Loading company…
Riskpilot
← Back to search
Sign in
Get full access
SERB NUF
NUF
Active
Org 924580941
Avenue Louise 480, Be-1050 Ixelles
Manufacture of pharmaceutical preparations · NACE 2120
Est. 2020
1 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 2,4M
EBITDA margin
5.0%
+104% vs 2023
Equity ratio
—
Financial strength
Net profit 2024
NOK 96K
+103% vs 2023
EBITDA — year on year
NOK millions
0M
0M
1M
1M
1M
-2M
2022
-3M
-50%
2023
0M
+100%
2024
Key figures
Annual report 2024
Revenue
NOK 2,4M
—
EBITDA
NOK 123K
+104%
Net profit
NOK 96K
+103%
Total assets
NOK 0
—
Equity
NOK -4,1M
+42%
Employees
1
—
Company information
Legal name
SERB NUF
Org number
924580941
Legal form
Norskregistrert Utenlandsk Foretak
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
19. februar 2020
Share capital
—
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Legemiddelproduksjon og farmasøytisk engros.
Contact
Address
Avenue Louise 480, Be-1050 Ixelles
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of pharmaceutical preparations
Companies in Be-1050 Ixelles
All Norway companies
Revenue
NOK millions
0M
1M
1M
2M
2M
0M
2022
0M
2023
2M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
-2M
2022
-3M
2023
0M
2024
Income statement
NOK thousands
Item
2022
2023
2024
Revenue
0
0
2 448
Staff expenses
−2 163
−2 735
−2 236
EBITDA
−2 207
−2 783
123
Depreciation & amort.
−0
−0
−0
EBIT
−2 207
−2 783
123
Net financials
0
0
0
Profit before tax
−2 207
−2 783
123
Tax
−0
−0
27
Net profit
−2 207
−2 783
96
Balance sheet
NOK thousands
Item
2022
2023
2024
Total assets
0
0
0
Equity
−2 207
−7 055
−4 068
Long-term debt
0
0
0
Short-term debt
2 207
7 055
4 068
Total debt
2 207
7 055
4 068
Financial ratios
5-year trend
EBITDA margin
5.0%
This company
15.8%
Market median
-68% vs market
2022
2024
Equity ratio
-406839500.0%
This company
38.2%
Market median
-1065024969% vs market
2022
2024
Return on equity
9580000.0%
This company
18.4%
Market median
+52065117% vs market
2022
2024
Net profit margin
3.9%
This company
8.1%
Market median
-52% vs market
2022
2024
Asset turnover
2448000.00×
This company
1.12×
Market median
+218571329% vs market
2022
2024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
LB
Luc Bodet
Contact Person
Contact Person
2020
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of SERB NUF also hold positions in
0
other companies.
Person
Role here
Other companies
Luc Bodet
Contact Person
0 companies